✦ LIBER ✦

A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer

✍ Scribed by Susan F. Dent; Stan Gertler; Shailendra Verma; Roanne Segal; Vince Young; Rakesh Goel; Oliver Keller; Christina Canil; Neill Iscoe

Publisher: Springer
Year: 2009
Tongue: English
Weight: 215 KB
Volume: 65
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1064-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of pemetrexed and carbo

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

✍ August Garin; Alexey Manikhas; Mikhail Biakhov; Mikhail Chezhin; Tatiana Ivanche 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 195 KB

Gemcitabine and vinorelbine as second-li

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study

✍ Michela Donadio; Mara Ardine; Alfredo Berruti; Giuliana Ritorto; Elena Fea; Mari 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 179 KB

A phase II trial of biweekly high dose g

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

✍ Herbert Ulrich-Pur; Gabriela V. Kornek; Markus Raderer; Karin Haider; Werner Kwa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Results of a phase II study of pemetrexe

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer

✍ Nicholas J. Robert; Paul R. Conkling; Mark A. O’Rourke; Paul R. Kuefler; Kristi 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 234 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi

Phase I dose-escalating study of biweekl

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors

✍ Yuan Yuan; Deirdre J. Cohen; Erica Love; Michelle Yaw; Benjamin Levinson; Steven 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 289 KB